Showing results (291-300 of 331) with videos related to

Sort By:
Pageof 34
Cancers|September 9, 2023
Radiomic Analysis of Intrahepatic Cholangiocarcinoma: Non-Invasive Prediction of Pathology Data: A Multicenter Study to Develop a Clinical-Radiomic ModelFrancesco Fiz, Noemi Rossi, Serena Langella, et al.
Annals of Surgical Oncology|May 26, 2024
Radiomics of Intrahepatic Cholangiocarcinoma and Peritumoral Tissue Predicts Postoperative Survival: Development of a CT-Based Clinical-Radiomic ModelFrancesco Fiz, Noemi Rossi, Serena Langella, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 26, 2024
Preoperative prediction of post hepatectomy liver failure after surgery for hepatocellular carcinoma on CT-scan by machine learning and radiomics analysesSimone Famularo, Cesare Maino, Flavio Milana, et al.
Annals of Surgery|December 18, 2024
External Validation of the ISGPS Complexity Grading System for Minimally Invasive Pancreatoduodenectomy: Insights from the IGOMIPS registryNiccolò Napoli, Greta Donisi, Emanuele F Kauffmann, et al.
Archives of Surgery (Chicago, Ill. : 1960)|January 18, 2012
Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patientsGennaro Nuzzo, Felice Giuliante, Francesco Ardito, et al.
Trials|July 27, 2020
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088)Igor Monsellato, Elisabetta Garibaldi, Elisa Cassinotti, et al.
Tumori|May 10, 2018
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocolAndrea Casadei Gardini, Luca Faloppi, Giuseppe Aprile, et al.
Cell Genomics|June 30, 2023
Proteomics of immune cells from liver tumors reveals immunotherapy targetsFernando P Canale, Julia Neumann, Janusz von Renesse, et al.
BMC Cancer|February 19, 2020
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
BMC Cancer|December 18, 2019
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)Igor Monsellato, Filippo Alongi, Elisa Bertocchi, et al.
Pageof 34